Skip to main content
S&P 5007,801.77-0.22%DOW51,179.87-0.66%NASDAQ27,538.69-0.22%BTC$83,372.00-2.51%ETH$2,574.91-4.55%GOLD$4,130.50-0.25%OIL$89.24+1.09%
Smart Investors Daily
SID Premium
LN

NASDAQ · LNTH

Lantheus Holdings, Inc.

Healthcare · Drug Manufacturers - Specialty & Generic

$100.18

Up+$0.23 (+0.23%)

Updated Oct 8, 2026, 4:10 AM

SID Score

4.8/10

Composite research score

Smart Money

58/100

Neutral

Market cap
4.32B
P/E ratio
25.3
Dividend yield
0.00%
52-week range
$72.35 – $111.86
Volume
553.78K
Avg. volume
1.36M

Price performance · LNTH

LNTH price history

1M range · 21 trading sessions · Daily adjusted prices

Prices through Oct 7, 2026

LNTH closed at $100.18 after 21 trading sessions, down 0.52% for the selected period.

Last close
$100.18
Period change
-0.52%
Period low
$99.51
Period high
$100.80
Daily close
View OHLC price history
LNTH OHLC price history, latest 40 sessions
DateOpenHighLowCloseVolume
Oct 7, 2026$100.20$100.33$100.02$100.18553.78K
Oct 6, 2026$100.28$100.34$99.89$99.95730.11K
Oct 5, 2026$100.00$100.28$99.95$100.19658.89K
Oct 2, 2026$99.78$100.07$99.695$99.96714.69K
Oct 1, 2026$99.52$99.79$99.52$99.65617.06K
Sep 30, 2026$99.55$99.74$99.31$99.531.81M
Sep 29, 2026$99.61$99.85$99.31$99.511.25M
Sep 28, 2026$99.68$99.955$99.61$99.741.25M
Sep 25, 2026$99.92$99.99$99.72$99.74952.39K
Sep 24, 2026$100.00$100.02$99.69$99.72938.57K
Sep 23, 2026$100.28$100.28$99.89$99.97865.43K
Sep 22, 2026$100.28$100.40$99.98$100.001.52M
Sep 21, 2026$100.96$100.96$100.22$100.28786.68K
Sep 18, 2026$100.79$100.96$100.48$100.551.03M
Sep 17, 2026$100.91$101.05$100.64$100.80612.12K
Sep 16, 2026$100.73$100.865$100.48$100.54746.92K
Sep 15, 2026$100.46$100.77$100.33$100.731.14M
Sep 14, 2026$100.47$100.52$100.155$100.321.29M
Sep 11, 2026$100.51$100.51$100.18$100.251.21M
Sep 10, 2026$100.65$100.98$100.37$100.39868.63K
Sep 9, 2026$100.45$101.02$100.45$100.70710.6K

Latest LNTH news

The latest Smart Investors Daily articles mentioning LNTH.

Stock researchCompany · Overview

LNTH research

Overview

Company profile and research snapshot.

Company profile

Lantheus Holdings Inc caters to the United States healthcare sector with the development of diagnostic products. Its products are in three categories: Precision Diagnostics, Radiopharmaceutical Oncology, and Strategic Partnerships and Other Revenue. Precision Diagnostic products assist healthcare professionals Find and Follow diseases, with a focus in cardiology. Radiopharmaceutical Oncology diagnostics and therapeutics help HCPs Find, Fight and Follow cancer. Strategic Partnerships focus on enabling precision medicine through the use of biomarkers, digital solutions and pharma services platforms, and also includes license of RELISTOR to Bausch Health Companies, Inc.

Visit company website

Analyst outlook

Consensus and target data currently published for this company.

Consensus
—
Average target
$78.50
Implied upside
—
Analysts
—
LNTH recent ratings
DateFirmRatingTarget
Aug 4, 2026CJS SecuritiesMarket Perform—
Aug 4, 2026Truist SecuritiesHold—
Aug 3, 2026TD CowenHold—
Aug 3, 2026William BlairMarket Perform—
Jul 29, 2026MizuhoOutperform—
Open full forecast

News briefing

No generated briefing is available yet.

Yahoo · Sep 26, 2026

Lantheus Holdings (LNTH) Could Be 7% Undervalued On BRAVNETSA Approval

FDA approval for BRAVNETSA puts Lantheus Holdings (LNTH) in focus Lantheus Holdings (LNTH) drew fresh attention after the FDA granted final approval for BRAVNETSA, a radiopharmaceutical considered bioequivalent and therapeutically equivalent to LUTATHERA for adult GEP NET patients. The BRAVNETSA approval lands at a time when Lantheus Holdings has seen short term share price pressure, with the stock down over the past three months. Yet its year to date share price return of 48.27% and 1 year...

Yahoo · Sep 26, 2026

Lantheus Holdings (LNTH) Stock May Be 14% Undervalued On FDA Approval

Lantheus Holdings has delivered a powerful 5 year share price run, and the recent pullback leaves investors asking whether the current US$99.74 level is still grounded in the cash the business can generate. With fresh product news in its core radiopharmaceutical line, the question now is how far those future cash flows can stretch to back up today's valuation. Over the past 5 years the stock has returned 285.5%, which puts real pressure on the cash flow outlook to carry that kind of value...

Yahoo · Sep 23, 2026

Strong Earnings, FDA Approval, and Takeover Interest Drive Lantheus Holdings’ (LNTH) Rally

Polaris Capital Management, an investment management company, released its second-quarter 2026 investor letter for “Global Equity Strategy”. The letter can be downloaded here. Global markets delivered strong gains during the quarter, supported by an AI-driven earnings rally despite elevated interest rates, inflation concerns, and geopolitical uncertainty. Polaris Global Equity Composite (net of fees) returned 13.26% […]

Yahoo · Sep 23, 2026

3 Reasons LNTH is Risky and 1 Stock to Buy Instead

Lantheus currently trades at $100.02 and has been a dream stock for shareholders. It’s returned 270% since September 2021, blowing past the S&P 500’s 74.5% gain. The company has also beaten the index over the past six months as its stock price is up 32.1% thanks to its solid quarterly results.

AI research layers

Interpretive context generated from the platform’s current data sources.

No results

AI research layers have not been published yet.

Featured By